Miguel Pastor Borgoñón

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Lara Carmen Iglesias Docampo, V. Arrazubi Arrula, N. Baste Rotllan et al. · Clinical & Translational Oncology · 2017 · 34 citations · Full text

Medicine, Oncology, Otolaryngology +9

Analysis of autophagy gene polymorphisms in Spanish patients with head and neck squamous cell carcinoma

Javier Fernández-Mateos, Raquel Seijas-Tamayo, Juan Carlos Adansa Klain et al. · Scientific Reports · 2017 · 29 citations · Full text

Medicine, Genetics, Oncology +17

Genetic Susceptibility in Head and Neck Squamous Cell Carcinoma in a Spanish Population

Javier Fernández-Mateos, Raquel Seijas-Tamayo, Juan Adansa Klain et al. · Cancers · 2019 · 27 citations · Full text

Medicine, Genetics, Oncology +16

Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population

Javier Fernández-Mateos, Raquel Seijas-Tamayo, Miren Taberna et al. · Oral Oncology · 2016 · 26 citations · Full text

Medicine, Oncology, Pharmacology +15